Amicus Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Amicus Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Amicus Therapeutics Inc Strategy Report
- Understand Amicus Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Amicus Therapeutics Lead Sheet
Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Amicus Therapeutics Inc’s relevant decision makers and contact details.
A sample of Amicus Therapeutics Lead Sheet data
| Lead Date | Lead Type | Lead Description | Company Name | Drug Name | Therapy Area |
|---|---|---|---|---|---|
| 08 Dec 2022 | GDCTWXYZ | Lorem | Lorem | Lorem | Cardiovascular |
| 11 Nov 2022 | Rescue Study | This company may need services for their Phase III trial Initiation | Amicus Therapeutics Inc | migalastat hydrochloride | Genetic Disorders; Genito Urinary System And Sex Hormones |
| 07 Nov 2022 | Capital Raisings | Amicus Therapeutics to Raise up to USD250 Million in Public Offering of Common Stock | Amicus Therapeutics Inc | (alglucosidase alfa + duvoglustat hydrochloride); (ATB-101 + migalastat hydrochloride); (cipaglucosidase alfa + miglustat); AAV9-CLN8; afegostat tartrate; AT-3375; ATGTX-502; ATGTX-701; CDKL5 Deficiency Disorder (CDD); Chaperone + ERT Combinations; chaperone + laronidase; duvoglustat hydrochloride; Enzyme Replacement Therapy + migalastat hydrochloride; Gene Therapy for Acid Sphingomyelinase Deficiency Type C; Gene Therapy for Inherited Metabolic Disorders; Gene Therapy for Tay-Sachs Disease; Gene Therapy for Wolman's Disease; Gene Therapy to Activate CLN1 for Batten Disease; Neurologic Lysosomal Disorders; Next Generation MPS IIIA; Next Generation MPS IIIB; Next-Generation Chaperone; Next-Generation Research Programs; Pompe Gene Therapy; Recombinant Enzymes for Cyclin-Dependent Kinase Like-5 deficiency; Recombinant Enzymes for Lysosomal Storage Disorder; Small Molecules for Alzheimer’s Disease; Small Molecules to Activate Glucosylceramidase for Parkinson's Disease | Central Nervous System; Genetic Disorders; Metabolic Disorders; Musculoskeletal Disorders |
| 21 Sep 2022 | Trial Results Announced | Phase III Trial Result (Pooled Results) announced on 21-Sep-2022 | Amicus Therapeutics Inc | (cipaglucosidase alfa + miglustat) | Metabolic Disorders |
Feature
Lead Sheet offers business development users in a Supplier Company, convenient access to leads within the biopharmaceutical industry.
- Lead: Any current or future events that signal a company may need services from another company in the near future.
Depending on the user’s company type, specific events may be considered a lead for the goods or services they provide.
Benefit
Leads within Lead Sheet fall into six major types of occurrences: Trial Events, Regulatory Events, Deals, Insights, New Companies, and Role Changes.
Some of these categories are broken out further to allow users the flexibility to filter to the event types they consider a lead.
Any lead type starting with “Expected” implies that it is a future event sourced from our Catalyst Calendar.
Value
Lead Sheet is a business development tool to help optimize sales efficiency
- What prospective accounts to target
- When and why to target them through actionable leads/opportunities
- Who to reach out to
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer